3 completed, 1 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Terminated 1 |
Follow ilorasertib: new trials by email Literature Review of ilorasertib trials Research Report on ilorasertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors Ilorasertib - Advanced Cancers | Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2016-08-05 | 2023-07-17 |
| Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery Ilorasertib, Laboratory Biomarker Analysis - Metastatic Malignant Neoplasm, Solid Neoplasm | Phase 1 | Completed | University of Chicago | 12 | 2015-09-08 | 2019-04-22 |
| ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies ABT-348, ABT-348 and azacitidine - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 1 | Completed | AbbVie (prior sponsor, Abbott) | 52 | 2010-04-01 | 2017-11-20 |
| ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors ABT-348, ABT-348 and carboplatin, ABT-348 and docetaxel - Advanced Solid Tumors | Phase 1 | Completed | AbbVie (prior sponsor, Abbott) | 102 | 2010-03-01 | 2013-11-06 |
Neoplasm Metastasis (2) · Anemia, Refractory, with Excess of Blasts (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
AbbVie (prior sponsor, Abbott) (2) · M.D. Anderson Cancer Center (1) · University of Chicago (1)
United States (4)
Gary Gordon, MD (2) · David S. Hong, MD (1) · Manish Sharma (1)
P30CA014599 (1)